Diagnosis and OutcoMes evaluAtIoN of Multicenter Patients With HFpEF Using Multimodality Imaging

Launched by CHINESE ACADEMY OF MEDICAL SCIENCES, FUWAI HOSPITAL · Oct 20, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a type of heart failure called heart failure with preserved ejection fraction (HFpEF). This condition is becoming more common, but doctors often struggle to recognize it early because standard imaging methods don’t always show the subtle changes in the heart. The goal of this study is to use advanced imaging techniques, along with data and artificial intelligence, to better understand the heart’s condition in patients with HFpEF. By doing this, researchers hope to improve early diagnosis and identify risk factors that could help manage this type of heart failure more effectively.

To participate in the study, individuals need to be experiencing symptoms of heart failure and have specific test results, such as a left ventricular ejection fraction of 50% or higher. They should also have certain abnormalities in their heart structure or function. However, people with specific heart conditions or severe issues, like serious arrhythmias or certain types of heart muscle diseases, won’t be eligible. If someone chooses to join the study, they can expect to undergo various imaging tests to provide a clearer picture of their heart health, contributing to important research that could lead to better care for others with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • left ventricular ejection fraction (LVEF)≥50%；
• • N-terminal pro-b type natriuretic peptide (NT-proBNP)\>220pg/ml or b type natriuretic peptide (BNP) \>80 pg/ml;
• • symptoms and syndromes of heart failure;
• • At least one criteria of cardiac structure (left ventricular hypertrophy, or left atrial enlargement) and function abnormalities (based on tissue doppler, color doppler).
• Exclusion Criteria:
• • Special types of cardiomyopathy, including hypertrophic cardiomyopathy, restricted cardiomyopathy, etc.
• • Infarction, myocardial fibrosis caused by ischemic cardiomyopathy and acute coronary syndrome ;
• • Severe arrhythmia;
• • Severe primary cardiac valvular disease;
• • Restrictive pericardial disease;
• • Refuse to participate in the study.